Andrew R Chapman,Kuan Ken Lee,David A McAllister,Louise Cullen,Jaimi H Greenslade,William Parsonage,Andrew Worster,Peter A Kavsak,Stefan Blankenberg,Johannes Neumann,Nils A Sörensen,Dirk Westermann,Madelon M Buijs,Gerard J E Verdel,John W Pickering,Martin P Than,Raphael Twerenbold,Patrick Badertscher,Zaid Sabti,Christian Mueller,Atul Anand,Philip Adamson,Fiona E Strachan,Amy Ferry,Dennis Sandeman,Alasdair Gray,Richard Body,Brian Keevil,Edward Carlton,Kim Greaves,Frederick K Korley,Thomas S Metkus,Yader Sandoval,Fred S Apple,David E Newby,Anoop S V Shah,Nicholas L Mills

Abstract:Importance: High-sensitivity cardiac troponin I testing is widely used to evaluate patients with suspected acute coronary syndrome. A cardiac troponin concentration of less than 5 ng/L identifies patients at presentation as low risk, but the optimal threshold is uncertain. Objective: To evaluate the performance of a cardiac troponin I threshold of 5 ng/L at presentation as a risk stratification tool in patients with suspected acute coronary syndrome. Data sources: Systematic search of MEDLINE, EMBASE, Cochrane, and Web of Science databases from January 1, 2006, to March 18, 2017. Study selection: Prospective studies measuring high-sensitivity cardiac troponin I concentrations in patients with suspected acute coronary syndrome in which the diagnosis was adjudicated according to the universal definition of myocardial infarction. Data extraction and synthesis: The systematic review identified 19 cohorts. Individual patient-level data were obtained from the corresponding authors of 17 cohorts, with aggregate data from 2 cohorts. Meta-estimates for primary and secondary outcomes were derived using a binomial-normal random-effects model. Main outcomes and measures: The primary outcome was myocardial infarction or cardiac death at 30 days. Performance was evaluated in subgroups and across a range of troponin concentrations (2-16 ng/L) using individual patient data. Results: Of 11 845 articles identified, 104 underwent full-text review, and 19 cohorts from 9 countries were included. Among 22 457 patients included in the meta-analysis (mean age, 62 [SD, 15.5] years; n = 9329 women [41.5%]), the primary outcome occurred in 2786 (12.4%). Cardiac troponin I concentrations were less than 5 ng/L at presentation in 11 012 patients (49%), in whom there were 60 missed index or 30-day events (59 index myocardial infarctions, 1 myocardial infarction at 30 days, and no cardiac deaths at 30 days). This resulted in a negative predictive value of 99.5% (95% CI, 99.3%-99.6%) for the primary outcome. There were no cardiac deaths at 30 days and 7 (0.1%) at 1 year, with a negative predictive value of 99.9% (95% CI, 99.7%-99.9%) for cardiac death. Conclusions and relevance: Among patients with suspected acute coronary syndrome, a high-sensitivity cardiac troponin I concentration of less than 5 ng/L identified those at low risk of myocardial infarction or cardiac death within 30 days. Further research is needed to understand the clinical utility and cost-effectiveness of this approach to risk stratification.

Age Variation in Patients with Troponin Level Elevation Without Obstructive Culprit Lesion or Suspected Myocardial Infarction with Non-Obstructive Coronary Arteries—Long-Term Data Covering over Decade

Age and Composite End-Point Events in Medium Follow-Up of Patients with Carotid Artery Total Occlusion Using Drug Therapy.

Causes of Troponin Elevation and Associated Mortality in Young Patients

Ejection Fraction-Related Differences of Baseline Characteristics and Outcomes in Troponin-Positive Patients without Obstructive Coronary Artery Disease

Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey

Association of High-Sensitivity Cardiac Troponin T with All-Cause and Cardiovascular Mortality in Older Adults with Low Lean Mass: A 14.6-Year Longitudinal Study.

Three-year changes in high-sensitivity cardiac troponin-T and total mortality in older adults

Elevated High Sensitivity Cardiac Troponin T is Nonlinearly Associated with Poor Prognosis in Aging COVID-19 Patients: A Retrospective Study.

The Impact of the Duration of Cardiac Troponin I Elevation on the Clinical Prognosis as Well as Incidence of New-Onset Atrial Fibrillation Respectively in Elderly Non-ST-Elevation Acute Myocardial Infarction Patients without PCI

Relationship between high-sensitivity cardiac troponin T and the prognosis of elderly inpatients with non-acute coronary syndromes.

Temporal trends in the treatment and outcome of nonagenarians with acute coronary syndrome

Octogenarians, nonagenarians and centenarians with myocardial infarction over time in Sweden

Evaluation of Age and Sex Differences in Contemporary versus High-Sensitivity Troponin I Measurement in Hospitalized Patients

Serial troponin-T and long-term outcomes in suspected acute coronary syndrome

Age-Sex Distribution Of Patients With High-Sensitivity Troponin T Levels Below The 99th Percentile

Sex Differences in Cardiac Troponin Trajectories Over the Life Course

High-sensitivity Cardiac Troponin T in Geriatric Inpatients.

European Society of Cardiology 0/1-hour algorithm (high-sensitivity cardiac troponin T) performance across distinct age groups

[The Effect of Age on the Clinical Outcomes of Patients with Acute Myocardial Infarction Treated by Direct Percutaneous Coronary Intervention].

Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome

Serial troponin-I and long-term outcomes in subjects with suspected acute coronary syndrome